Trulieve Wins NYSE Approval as First US Cannabis Operator

Trulieve Cannabis Corp. (TRLV ) is two trading days from opening on the New York Stock Exchange — the first US cannabis company to clear that bar — after the NYSE formally approved its shares for listing on June 5, 2026. Trading under the ticker TRLV is set to begin at the June 10, 2026 open, ending a decades-long exclusion of domestic cannabis operators from America’s mainstream capital markets.

That exclusion didn’t lift through lobbying or litigation. It lifted because the federal government moved state-licensed medical cannabis off Schedule I this spring. That shift in federal drug law created, for the first time, a legal pathway for a US cannabis company to meet NYSE listing requirements — and Trulieve moved quickly to build the corporate structure needed to walk through it.

How the Restructuring Made the Listing Possible

Getting to the NYSE required Trulieve to surgically separate its medical cannabis operations from its adult-use business. In a current report filed with the SEC on June 3, 2026, the company disclosed that it had completed a deconsolidation of its Harvest Enterprises subsidiary — the entity holding Trulieve’s mixed-use and adult-use cannabis operations — from the parent company’s consolidated financial statements.

The mechanics: a third-party investor identified in the filing as Whitley Holding 05192026 LLC acquired a 10% economic ownership stake in Harvest for approximately $14.8 million, taking on voting control of that entity. Trulieve retains a non-voting, non-participating interest in Harvest — one that can only convert to a full economic stake if and when the NYSE decides it will permit listed companies to consolidate the financial results of entities holding marijuana for non-medical uses in the United States. Until that happens, which would require further exchange rule changes or additional federal action, the adult-use operations sit in a separately governed entity outside the NYSE-listed company.

What remains on the NYSE-eligible side of the ledger is Trulieve’s medical-only footprint: 206 dispensaries and 3.5 million square feet of production capacity, all registered with the DEA following the April 23, 2026 rescheduling order. The company’s shares had been trading on the Canadian Securities Exchange under TRUL and on the OTCQX market under TCNNF; both listings are expected to close on June 9, 2026.

In the June 5, 2026 announcement of NYSE approval, CEO Kim Rivers called the listing “a historic milestone” and credited the Trump administration’s decision to reclassify medical marijuana to Schedule III as what “paved the way.” The company said the NYSE listing will broaden its shareholder base, increase liquidity, and bring awareness to the medical cannabis sector — investor access and visibility that OTC trading simply cannot provide.

The Legal Overhang Investors Need to Know

The rescheduling order that made all of this possible is facing a coordinated legal challenge, and Trulieve’s investors are exposed to that risk.

The attorneys general of Indiana and Nebraska filed suit in the US Court of Appeals for the DC Circuit in early June 2026, arguing the April 23, 2026 rescheduling order is arbitrary and unlawful, and that it exceeds the authority of the Attorney General. The DC Circuit consolidated that challenge with an earlier complaint from the prohibitionist group SAM Inc. and the National Drug and Alcohol Screening Association, which made similar arguments when it filed in May 2026. Louisiana’s attorney general was initially a co-petitioner but subsequently moved to withdraw from the case.

No court has issued a stay of the rescheduling order, so the DEA registration pathway and the NYSE listing proceed unpaused. But the consolidated lawsuit represents the most significant court-level challenge to the legal foundation underpinning Trulieve’s exchange eligibility. If the order were ultimately vacated, the regulatory basis for the NYSE listing could unravel.

Separately, the DEA is scheduled to hold its own administrative hearings beginning June 29, 2026, on a different question: whether all botanical cannabis, beyond the state-licensed medical products covered by the April 23 order, should also move to Schedule III. That proceeding traces to a 2023 rulemaking proposal from the Department of Health and Human Services and runs through mid-July. The court challenge and the DEA administrative process are legally distinct but together frame the degree of policy uncertainty that still surrounds the landscape that made the Trulieve listing possible.

What Comes Next for Cannabis Capital Markets

Trulieve has done something replicable: it identified the structural move required to qualify a cannabis operator for major-exchange listing and executed it in a matter of weeks after the rescheduling order landed. The deconsolidation playbook — separating a DEA-registered medical business from adult-use operations in a way that satisfies exchange listing requirements — is now documented in an SEC filing that other operators can study.

Whether other operators follow will depend on whether they have separable medical operations of sufficient scale and whether they’re willing to accept the same trade-off Trulieve made: gain institutional exchange access now, but put the adult-use upside behind a wall that only further federal action can remove. That’s a bet on the direction of federal policy — and, more immediately, on the courts not reversing the April 23 order that brought them to this point. The federal rescheduling of state-licensed medical cannabis to Schedule III is now both the foundation of Trulieve’s market milestone and the subject of its most significant unresolved risk.